XML 77 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue Recognition
 9 Months Ended
Apr. 30, 2020
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue RecognitionWe adopted ASC 606, effective August 1, 2018, using the modified retrospective method applied to those contracts which were not completed as of August 1, 2018. Due to the cumulative impact of adopting ASC 606, we recorded a net increase of $865 to opening retained earnings, net of tax, as of August 1, 2018. The impact is primarily related to the timing of revenue recognition for the shipment of products in both our Medical and Life Sciences segments where risk of loss provisions are present (“synthetic FOB destination”). The new standard does not require us to defer revenue for these products and allows us to recognize revenue at the time of shipment. The cumulative adjustment to retained earnings also includes the impact of the change in timing of revenue recognition associated with software licensing arrangements in our Medical segment. Additionally, revenue related to software renewals was historically recognized on a ratable basis over the license period. Under ASC 606, the license is considered functional intellectual property, and is considered to be transferred to the customer at a point in time, specifically, at the start of each annual renewal period. As a result, revenue related to our annual software license renewals has been accelerated.
The following table gives information as to the net sales disaggregated by geography and product line:
 Three Months Ended April 30,Nine Months Ended April 30,
Net sales by geography2020201920202019
United States$176,688  $163,367  $574,370  $497,469  
Europe/Africa/Middle East37,518  39,949  128,032  106,278  
Asia/Pacific14,766  15,140  54,097  46,476  
Canada6,448  8,555  22,026  24,064  
Latin America/South America1,513  1,541  4,152  4,392  
Total$236,933  $228,552  $782,677  $678,679  
Net sales by product line
Capital equipment$50,589  $51,351  $169,061  $166,870  
Consumables131,486  144,515  438,974  417,067  
Product service29,243  31,074  92,374  91,428  
Instrument sales25,040  —  79,381  —  
All other(1)
575  1,612  2,887  3,314  
Total$236,933  $228,552  $782,677  $678,679  
_______________________________________________
(1)Primarily includes software licensing revenues.

Remaining Performance Obligations

At April 30, 2020, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $75,948, primarily within the Medical segment. We expect to recognize revenue on approximately 60% of these remaining performance obligations over the remainder of fiscal 2020 and fiscal 2021. These performance obligations primarily reflect the future product service revenues for multi-period service arrangements.

Contract Liabilities

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Our contract liabilities arise primarily in the Medical and Life Sciences segments when payment is received upfront for various multi-period extended service arrangements. We expect to recognize substantially all of this revenue over the next twelve months.

A summary of contract liabilities activity follows:
Nine Months Ended April 30,
20202019
Beginning balance$28,235  $29,015  
Revenue deferred in current year41,733  48,589  
Deferred revenue recognized(42,705) (49,710) 
Foreign currency translation(70) (435) 
Ending balance27,193  27,459  
Contract liabilities included in Other long-term liabilities(309) (824) 
Deferred revenue$26,884  $26,635